1. Home
  2. LFMD vs ESPR Comparison

LFMD vs ESPR Comparison

Compare LFMD & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LFMD
  • ESPR
  • Stock Information
  • Founded
  • LFMD 1994
  • ESPR 2008
  • Country
  • LFMD United States
  • ESPR United States
  • Employees
  • LFMD N/A
  • ESPR N/A
  • Industry
  • LFMD Medical/Nursing Services
  • ESPR Biotechnology: Pharmaceutical Preparations
  • Sector
  • LFMD Health Care
  • ESPR Health Care
  • Exchange
  • LFMD Nasdaq
  • ESPR Nasdaq
  • Market Cap
  • LFMD N/A
  • ESPR 305.0M
  • IPO Year
  • LFMD N/A
  • ESPR 2013
  • Fundamental
  • Price
  • LFMD $8.16
  • ESPR $0.89
  • Analyst Decision
  • LFMD Strong Buy
  • ESPR Buy
  • Analyst Count
  • LFMD 6
  • ESPR 7
  • Target Price
  • LFMD $11.17
  • ESPR $5.93
  • AVG Volume (30 Days)
  • LFMD 2.1M
  • ESPR 5.7M
  • Earning Date
  • LFMD 05-06-2025
  • ESPR 05-06-2025
  • Dividend Yield
  • LFMD N/A
  • ESPR N/A
  • EPS Growth
  • LFMD N/A
  • ESPR N/A
  • EPS
  • LFMD N/A
  • ESPR N/A
  • Revenue
  • LFMD $234,007,330.00
  • ESPR $259,574,000.00
  • Revenue This Year
  • LFMD $29.08
  • ESPR $5.70
  • Revenue Next Year
  • LFMD $18.81
  • ESPR N/A
  • P/E Ratio
  • LFMD N/A
  • ESPR N/A
  • Revenue Growth
  • LFMD 43.07
  • ESPR 12.99
  • 52 Week Low
  • LFMD $3.99
  • ESPR $0.82
  • 52 Week High
  • LFMD $10.70
  • ESPR $3.94
  • Technical
  • Relative Strength Index (RSI)
  • LFMD 68.73
  • ESPR 36.95
  • Support Level
  • LFMD $7.11
  • ESPR $0.93
  • Resistance Level
  • LFMD $8.54
  • ESPR $1.11
  • Average True Range (ATR)
  • LFMD 0.57
  • ESPR 0.10
  • MACD
  • LFMD 0.20
  • ESPR 0.02
  • Stochastic Oscillator
  • LFMD 84.99
  • ESPR 25.10

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Share on Social Networks: